Michael F. Driscoll
Experienced in Bladder Cancer

Dr. Michael F. Driscoll

Oncology
676 South Floyd Street, 
Louisville, KY 
On Staff At
Accepting New Patients
Offers Telehealth
21 Years of Experience
Experienced in Bladder Cancer
676 South Floyd Street, 
Louisville, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Driscoll is an Oncologist in Louisville, Kentucky. Dr. Driscoll has been practicing medicine for over 21 years and is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Lynch Syndrome. Dr. Driscoll is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Louisiana State University At Shreveport, Doctor Of Medicine, 2005
Residency
University of Louisville School of Medicine, Internal Medicine, 2008
Specialties
Oncology
Licenses
Internal Medicine in KY
Board Certifications
American Board Of Internal Medicine, Medical Oncology - 2011
American Board Of Internal Medicine, Internal Medicine - 2008
Fellowships
University of Louisville School of Medicine, Hematology, 2011
Hospital Affiliations
Norton Hospitals, Inc
UOFL HEALTH - JEWISH HOSPITAL And Mary & Elizabeth Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MHS
  • EPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Norton Cancer Institute - Downtown
676 South Floyd Street, Louisville, KY 40202
Other Locations
Norton Cancer Institute - Audubon
2355 Poplar Level Road, Suite 405, Louisville, KY 40217

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
View 3 Less Clinical Trials

1 Total Publications

Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin.
Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin.
Journal: Annals of surgical oncology
Published: February 07, 2022
Similar Doctors
Chandler H. Park
Advanced in Bladder Cancer
Dr. Chandler H. Park
Oncology
Advanced in Bladder Cancer
Dr. Chandler H. Park
Oncology

Norton Cancer Institute - Elizabethtown

157 Towne Drive, Suite 103, 
Elizabethtown, KY 
 (36.0 miles away)
502-629-2500
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chandler Park is an Oncologist in Elizabethtown, Kentucky. Dr. Park has been practicing medicine for over 19 years and is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, WT1-Related Wilms Tumor Syndromes, and Urothelial Cancer. Dr. Park is currently accepting new patients.

Advanced in Bladder Cancer
Dr. Donald Goodin
Hematology | Oncology
Advanced in Bladder Cancer
Dr. Donald Goodin
Hematology | Oncology

Hardin Memorial Health Cancer Studies

521 Robinbrooke Blvd, 
Elizabethtown, KY 
 (35.5 miles away)
270-706-1535
Languages Spoken:
English
See accepted insurances

Donald Goodin is a Hematologist and an Oncologist in Elizabethtown, Kentucky. Dr. Goodin is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Lung Cancer.

Joseph J. Maly
Experienced in Bladder Cancer
Dr. Joseph J. Maly
Oncology
Experienced in Bladder Cancer
Dr. Joseph J. Maly
Oncology

Norton Cancer Institute - St. Matthews

3991 Dutchmans Lane, Suite 405, 
Louisville, KY 
 (5.1 miles away)
502-899-3366
Experience:
15+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Maly is an Oncologist in Louisville, Kentucky. Dr. Maly has been practicing medicine for over 15 years and is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndrome (MDS), Multiple Myeloma, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Maly is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Driscoll's expertise for a condition
ConditionClose
    View All 20 Distinguished Conditions
    View All 26 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile